Download in electronic PDF format for $25

Kalchem International - Chemicals and Compounding Supplies

Search the Complete Journal Archives

Pharmacogenomics: The End of Trial-and-Error Medicine?

Author(s):  Vail Jane

Issue:  Jan/Feb 2007 - Pediatric Patients
View All Articles in Issue

Abstract:  “The right dose of the right drug for the right indication for the right patient at the right time.” In those words, Dr. Felix Frueh captured the essence of pharmacogenomics and the goal of all compounding pharmacists. Pharmacogenomics provides the tools for prescribing personalized drug therapy that will improve treatment outcomes, decrease the incidence of drug-related adverse effects, and ultimately reduce the cost of medical care. The use of pharmacogenomics in clinical practice is changing as new discoveries make it possible and cost-effective to identify a patient’s unique genetic makeup and apply this information to treating medical ailments. With a prescription and the patient’s pharmacogenomic profile in mind, a compounding pharmacist can prepare a customized medication that delivers that patient’s unique best dosage in the optimal dosage form.

Related Keywords: PERSONALIZED MEDICINE, INDIVIDUALIZED MEDICINE, PHARMACOGENOMICS, GENOMICS, GENOME, GENETIC TESTING, RESEARCH, FDA, US FOOD AND DRUG ADMINISTRATION, TRIAL, CUSTOMIZED, JANET WOODCOCK

Related Categories: LEGAL, TECHNOLOGY, PROFESSIONAL ISSUES, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun Mar/Apr 2018 108-121 Buy
Pharmacogenomics: The End of Trial-and-Error Medicine? Vail Jane Jan/Feb 2007 59-65 Buy
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr Sep/Oct 2017 356 Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample
Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2 Allen Loyd V Jul/Aug 2015 280-287 Buy
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G Jul/Aug 2015 303-305 Buy
Pharmacogenomics: Precision Pharmacy in 503A Compounding Drummond Joseph, Bennet Daron, Allen Loyd V Jr Mar/Apr 2018 95-107 Buy
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr Nov/Dec 2015 487-488 Buy
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug Mar/Apr 2017 95-102 Buy
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G May/Jun 2014 208 Buy